Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2019 Earnings Conference Call Transcript
May 08, 2019 • 08:00 am ET
Good morning, and welcome to the Aquestive Therapeutics First Quarter 2019 Conference Call. At this time, all participants are now listen-only mode. Later, we'll conduct the question-and-answer session and instructions will be given at that time. (Operator Instructions) As a reminder, this call will be recorded.
I would now like to introduce your host for today's conference, Ms. Lauren Walrath, Head of Corporate Marketing and Communications. You may begin.
Thank you, operator. Good morning, and welcome to today's call to review Aquestive Therapeutics' results for the first quarter 2019. On today's call, I'm joined by Keith Kendall, Chief Executive Officer; Ken Marshall, Chief Commercial Officer; Dan Barber, Chief Strategy and Development Officer; John Maxwell, Chief Financial Officer and Lori Braender, General Counsel. Over the course of this call, we will provide an overview of business developments through Q1 of this year and discuss the progress we continue to make with respect to our 2019 goals and performance targets. Following these remarks, we will open the call to your questions. We expect today's call to last approximately 60 minutes in total.
As a reminder, our remarks today correspond with the press release we issued this morning. In addition, a recording and transcript of today's call will be made available on Aquestive Therapeutics' website within the Investor Relations section shortly following the conclusion of this call. During the call, the Company will be making forward-looking statements. We remind you of the Company's safe harbor language as outlined in today's press release, as well as the risks and uncertainties affecting the Company as described in the risk factors section included in the Company's Form 10-Q to be filed with the SEC on May 8, 2019.
As with any pharmaceutical product candidate under development, there are significant risks with respect to the development, regulatory approval and commercialization of new products. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to Aquestive Therapeutics or any person acting on behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update its forward-looking statements after the date of this conference call, whether as a result of new information, future events or otherwise, except as required under applicable law.
With that, I will now turn the line over to Keith.
Keith J. Kendall
Thank you, Lauren. Thank you, everyone for joining us this morning. We are pleased with the start of the year for Aquestive Therapeutics and the early progress we've made toward achieving our 2019 goals. Through the first quarter, the Company has continued to enjoy a strong book of business from our licensed products especially Suboxone. More importantly, we've made significant strides in advancing the next generation of medicines from our pipeline, which will support the future growth and success of Aquestive.
Looking ahead, we expect 2019 to be a formative year for the Company, as we work to achieve several commercial, regulatory and development milestones.